Tripod Therapeutics
Company

Tripod Therapeutics

Biotechnology Research 6 employees
Employees
6

Tripod Therapeutics Overview

Industry
Biotechnology Research
Employees
6
Founded
2021
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About Tripod Therapeutics

Tripod Therapeutics develops a first in class anti-cancer drug that targets a novel mechanism of action related to Proteasome dynamics. The technology was developed by Nobel laureate Professor Aaron Ciechanover and his team from the Israeli Institute of Technology ("Technion").

Compare Similar Companies to Tripod Therapeutics